Viatris and Biocon Launch Semglee (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) for the Treatment of Diabetes in the US
Shots:
- The companies launch Semglee and Insulin Glargine as interchangeable biosimilars products to improve patients' access with type 1 & 2 diabetes. Biocon and Viatris have co-developed both biosimilars products
- Both biosimilars products are available in a vial and prefilled pen presentations & will allow pharmacy level substitution for the reference product, Lantus across the US. Semglee is expected to be phased out at the end of 2021
- Viatris has established multiple options for patients including a patient assistance program to provide free products to eligible patients with financial need, Copay program for eligible commercially-insured patients along with other programs
Ref: PR Newswire | Image: Viatris
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com